Special SBIR online class creates opportunity for Faculty and Students

Students and Faculty on the biosciences – did you know that the same federal agencies (like DOD, NIH and NSF) that funded your initial research may provide you with grants of up to $100,000 (phase 1) and $1 million (phase 2) to commercialize that very same research under the $2.5 billion federal SBIR program awarded annually. The federal government desperately needs entrepreneurial researchers to create jobs over the next ten years to solve the country’s economic problems, and will support those researchers that show they can do it with SBIR funding (and other new major research commercialization programs now under consideration by the federal government). Researchers who can commercialize research are in great demand.

Are they looking for you?
In particular, the federal government would like to attract faculty, grad students and post-docs that need to find a job in the next 6 -18 months into the SBIR program.  If you or your students would like to learn more about research commercialization and the SBIR program, please register for the Research Commercialization Introductory Course starting Friday.   This FREE course is a great resource opportunity for you to learn how to move your innovations forward faster.
Register now for the Research Commercialization Introductory Course Starting Friday April 15

The Research Commercialization Introductory Online Course is designed to help researchers better understand what research commercialization really is and how it works. This is a very popular online course with generally over 1000 researchers taking it each time it is offered. It is taught by government and industry experts.
The Research Commercialization Course is recommended for all science, engineering and medical researchers in public or private research institutions (especially grad students, post-docs, and faculty). This is an indispensable course for S&E grad students looking for jobs in the next 6-18 months.

Research can be commercialized in a number of ways. Your research will likely result in various artifacts, such as articles, documentation, know-how, patents, and copyrights, and it is these artifacts that are commercialized in one form or another. Most commonly, research is commercialized by the researcher being employed by a company or lab. (This also can be as an independent contractor in the form of a part-time consulting agreement). In some cases, commercialization might take the form of licensing patents to an independent company. In rare but important cases, it might take the form of creating a startup by you and your colleagues. In all cases, though, research commercialization typically involves defining the nature of the research being commercialized (e.g., in a patent or intellectual property agreement), establishing a commercial relationship with another party (e.g., employment, a sale or license), and negotiating a contract (e.g., compensation).
Areas covered in the course include intellectual property, patents, copyrights, trade secrets, trademarks, licensing agreements, employment agreements, consulting agreements, tech transfer, creating and funding companies, and federally funded Small Business Innovation Research (SBIR) programs

Each lecture is a live 90-minute online class with Q&A.
Please forward this announcement to S&E graduate students and post-docs.

This workshop course is offered free of charge but registration is required.
Click here to register or go to https://www2.gotomeeting.com/register/750397178

Registered students who achieve 60% or greater on the final online multiple-choice test at the end of the program will be granted a Certificate of Successful Completion for this course.

Class Schedule:
Lecture 1: The Importance of Commercializing Research
Friday, April 15, 2011, 1:00 pm to 2:30 pm ET
Panelists: Steve Ferguson (NIH), Henry Wixon (NIST), Frank Barros (DHS)
Lecture 2: Patents, Copyright, Trademarks and Trade Secrets
Monday, April 18, 2011, 1:00 pm to 2:30 pm ET
Panelists: Henry Wixon (NIST), Bruce Goldstein (NIH)
Lecture 3: Employment and Consulting Agreements
Friday, April 22, 2011, 1:00 pm to 2:30 pm ET
Panelists: Ed Clancy (ACTA Technology, Inc), Robert Stulberg (Rothman & Stulberg, LLP)
Lecture 4: Tech Transfer and Licensing Agreements
Monday, April 25, 2011, 1:00 pm to 2:30 pm ET
Panelists: Mojdeh Bahar (NIH), Steve Ferguson (NIH)
Lecture 5: Small Business Innovation Research (SBIR) Grants
Friday, April 29, 2011, 1:00 pm to 2:30 pm ET
Panelists: Frank Barros (DHS), Ali Andalibi (NIH), Christine Villa (BRTRC, Inc.)
Lecture 6: The Research-Intensive Company and Early Stage Funding
Monday, May 2, 2011, 1:00 pm to 2:30 pm ET
Panelist: Ashley Stevens (Boston University)

Co-Organizers and Co-Moderators:
Ali Andalibi : Program Director| National Cancer Institute| SBIR Development Center
National Institutes of Health
Clara Asmail: Sr. Technical Advisor|  NIST Manufacturing Extension Partnership formerly SBIR Program Manager
National Institute of Standards and Technology (NIST)
Manufacturing Extension Partnership (MEP)
Frank Barros: SBIR Program Analyst | Department of Homeland Security (DHS)
Steve Ferguson
Deputy Director, Licensing & Entrepreneurship | Office of Technology Transfer
National Institutes of Health (NIH)
Juan E. Figueroa
Division of Industrial Innovation and Partnership
National Science Foundation (NSF)
Tony Stanco
Executive Director
National Council Of Entrepreneurial Tech Transfer
Christine Villa
Chief Technology Officer, BRTRC, Inc.
Principal Consultant, DOD SBIR/STTR Programs

For more information about this webinar contact NCET  at support@ncet2.org or visit http://center.ncet2.org
* If you are unable to view/click on the registration link, contact us at support@ncet.org

Ralph Martel

Many thanks to Dr. Ralph Martel, Chief Technology Officer of  of C-Path and a member of the AZBio Board of Directors for sharing this great opportunity.

The Critical Path Institute (C-Path) , founded in 2005 in Tucson, Arizona, is an independent, non-profit organization dedicated to bringing scientists from the FDA, industry, and academia together to improve the path for innovative new drugs, diagnostic tests and devices to reach patients in need.

Prior to joining C-Path, Dr. Martel served as Vice President for Research and Development, at High Throughput Genomics (HTG) where he led the commercialization of the company’s reagents, consumables, instruments, software and services to enable genomics-driven drug discovery using HTG’s patented multiplexed mRNA assays. Prior to that, he worked at Ventana Medical Systems where he was an inventor of Ventana’s patented detection kits for automated immunohistochemistry and in situ hybridization. In addition, he developed 12 marketed products that are FDA-approved for in vitro diagnostics. He graduated from Lehigh University with a B.S. in biochemistry and he received his PhD in Biochemistry and his MBA from The University of Arizona.

Posted in Opportunities and tagged , , , , , .